# Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

> **NCT07064525** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 252 (estimated)

## Conditions studied

- Hypertension (HTN)
- NYHA Class III Heart Failure
- NYHA Class IV Heart Failure
- Diabete Mellitus

## Interventions

- **DRUG:** SPC1001 Low
- **DRUG:** SPC5002
- **DRUG:** SPC5003
- **DRUG:** SPC5004

## Key facts

- **NCT ID:** NCT07064525
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-05
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-02-28
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064525, "Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07064525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*